Shirley Sze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shirley Sze has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Pierpaolo Pellicori
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
6 shared publications - Iain B. Squire
Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
4 shared publications - Manish Pareek
Department of Respiratory Sciences, University of Leicester, Leicester, UK
4 shared publications Andrew L. Clark
Department of Cardiovascular Science, National Institute for Health Research Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom
3 shared publications- Chokanan Thaitirarot
Department of Cardiology, Glenfield Hospital, University Hospitals of Leicester NHS Trust, LE3 9QP, UK; Cardiology Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand
3 shared publications - Daniel Pan
Department of Respiratory Sciences, University of Leicester, Leicester, UK
3 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
Multidimensional and Multidisciplinary Management of Heart Failure Patients with Frailty
This paper discusses the considerations for multidimensional and multidisciplinary management of heart failure (HF) patients with frailty. Frailty is a multidimensional, dynamic and potentially reversible state, defined by clinical, functional, psycho-cognitive and social domains. Frailty is seldom systematically assessed in clinical practice in HF patients. Paradoxically, although the absolute benefit of HF guideline-directed medical treatment in frail HF patients seems greater, it is under-prescribed. This therapeutic gap could be related to different reasons, such as concerns about safety, polypharmacy and the lack of specific evidence-based data. Frail HF patients require a comprehensive, multidimensional therapeutic strategy that integrates available evidence-based pharmacological interventions with targeted non-pharmacological modalities across multiple clinical disciplines to optimise patient outcomes. The four domains of frailty should be objectively and routinely assessed with a multidimensional approach to facilitate a more individualised and comprehensive care plan delivered by a multidisciplinary team. In the future, we need more dedicated studies and randomised clinical trials that include frail HF patients.
- 3 August 2026
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
Open AccessMultidimensional and Multidisciplinary Management of Heart Failure Patients with Frailty
This paper discusses the considerations for multidimensional and multidisciplinary management of heart failure (HF) patients with frailty. Frailty is a multidimensional, dynamic and potentially reversible state, defined by clinical, functional, psycho-cognitive and social domains. Frailty is seldom systematically assessed in clinical practice in HF patients. Paradoxically, although the absolute benefit of HF guideline-directed medical treatment in frail HF patients seems greater, it is under-prescribed. This therapeutic gap could be related to different reasons, such as concerns about safety, polypharmacy and the lack of specific evidence-based data. Frail HF patients require a comprehensive, multidimensional therapeutic strategy that integrates available evidence-based pharmacological interventions with targeted non-pharmacological modalities across multiple clinical disciplines to optimise patient outcomes. The four domains of frailty should be objectively and routinely assessed with a multidimensional approach to facilitate a more individualised and comprehensive care plan delivered by a multidisciplinary team. In the future, we need more dedicated studies and randomised clinical trials that include frail HF patients.
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (3)
Twiddler’s syndrome in extravascular implantable cardioverter-defibrillator: a case report
Background: Twiddler’s syndrome is caused by rotation of the pulse generator, which could lead to device malfunction. It has been reported in patients with transvenous and subcutaneous defibrillators but not in those with extravascular implantable cardioverter-defibrillators (EV-ICDs). Case summary: A 57-year-old man with an extraction for infected transvenous ICD (TV-ICD) underwent an EV-ICD for primary prevention. Device checks pre-discharge and at 6 weeks were unremarkable. However, 3 months post-implant, the patient experienced an inappropriate shock due to oversensing of noise. Chest X-ray revealed lead displacement, with the device rotated nearly 180° with the lead wrapped around it. Surgical revision confirmed lead coiling and torn fascia sutures, consistent with Twiddler’s syndrome. Discussion: This is the first reported case of Twiddler’s syndrome in a patient with an EV-ICD, presenting with inappropriate shock due to oversensing of noise. Clinicians should consider Twiddler’s syndrome as a potential cause of lead dislodgment and EV-ICD malfunction. Early recognition is crucial to enable timely intervention, restore device function, and prevent further complications.
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (3)
Open AccessTwiddler’s syndrome in extravascular implantable cardioverter-defibrillator: a case report
Background: Twiddler’s syndrome is caused by rotation of the pulse generator, which could lead to device malfunction. It has been reported in patients with transvenous and subcutaneous defibrillators but not in those with extravascular implantable cardioverter-defibrillators (EV-ICDs). Case summary: A 57-year-old man with an extraction for infected transvenous ICD (TV-ICD) underwent an EV-ICD for primary prevention. Device checks pre-discharge and at 6 weeks were unremarkable. However, 3 months post-implant, the patient experienced an inappropriate shock due to oversensing of noise. Chest X-ray revealed lead displacement, with the device rotated nearly 180° with the lead wrapped around it. Surgical revision confirmed lead coiling and torn fascia sutures, consistent with Twiddler’s syndrome. Discussion: This is the first reported case of Twiddler’s syndrome in a patient with an EV-ICD, presenting with inappropriate shock due to oversensing of noise. Clinicians should consider Twiddler’s syndrome as a potential cause of lead dislodgment and EV-ICD malfunction. Early recognition is crucial to enable timely intervention, restore device function, and prevent further complications.
- Open Access
- 25 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (21) , 2686-2696
Frailty and long-term outcomes in younger patients with acute myocardial infarction
Background and Aims: Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction (AMI), but its impact in younger patients remains underexplored. The aims of this study were to evaluate the association of frailty with adverse outcomes in AMI patients, stratified by age. Methods: This population-based epidemiological study utilized linked national administrative data from England and Wales. Patients were stratified into three age groups: <55 years, 55–74 years, and ≥75 years. Frailty was assessed using the Secondary Care Administrative Records Frailty index with patients categorized into fit, mild, moderate, and severe groups. All-cause mortality at 1 year was the primary outcome. Secondary outcomes were cardiovascular and bleeding-related events. Results: A total of 931 133 patients were included of which 13% of patients were severely frail. In patients with severe frailty, adjusted hazard ratios for all-cause mortality were 6.69 [95% confidence interval (CI) 5.76–7.76] for young patients, 4.33 (95% CI 4.11–4.57) for middle-aged patients, and 2.31 (95% CI 2.23–2.39) for older patients. The interaction between age and frailty revealed that younger patients with severe frailty had a 3.51-fold (95% CI 3.11–3.96) higher risk of all-cause mortality compared with older patients with severe frailty (P < .001). Conclusions: Frailty is independently associated with poor outcomes after AMI, with the strongest impact observed in younger patients, highlighting the need for frailty assessment across all age groups.
- 25 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (21) , 2686-2696
Open AccessFrailty and long-term outcomes in younger patients with acute myocardial infarction
Background and Aims: Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction (AMI), but its impact in younger patients remains underexplored. The aims of this study were to evaluate the association of frailty with adverse outcomes in AMI patients, stratified by age. Methods: This population-based epidemiological study utilized linked national administrative data from England and Wales. Patients were stratified into three age groups: <55 years, 55–74 years, and ≥75 years. Frailty was assessed using the Secondary Care Administrative Records Frailty index with patients categorized into fit, mild, moderate, and severe groups. All-cause mortality at 1 year was the primary outcome. Secondary outcomes were cardiovascular and bleeding-related events. Results: A total of 931 133 patients were included of which 13% of patients were severely frail. In patients with severe frailty, adjusted hazard ratios for all-cause mortality were 6.69 [95% confidence interval (CI) 5.76–7.76] for young patients, 4.33 (95% CI 4.11–4.57) for middle-aged patients, and 2.31 (95% CI 2.23–2.39) for older patients. The interaction between age and frailty revealed that younger patients with severe frailty had a 3.51-fold (95% CI 3.11–3.96) higher risk of all-cause mortality compared with older patients with severe frailty (P < .001). Conclusions: Frailty is independently associated with poor outcomes after AMI, with the strongest impact observed in younger patients, highlighting the need for frailty assessment across all age groups.
- Open Access
- 18 March 2025
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 58, 101649
Expert opinion on a safe same day discharge strategy as standard of care after leadless pacemaker implantation
- 18 March 2025
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 58, 101649
Open AccessExpert opinion on a safe same day discharge strategy as standard of care after leadless pacemaker implantation
- Open Access
- 21 February 2025
- Published by Elsevier in Clinical Medicine
- Vol. 25 (2) , 100296
Early and rapid initiation of quadruple therapy for heart failure with reduced ejection fraction: A real-world experience
- 21 February 2025
- Published by Elsevier in Clinical Medicine
- Vol. 25 (2) , 100296
Open AccessEarly and rapid initiation of quadruple therapy for heart failure with reduced ejection fraction: A real-world experience
- Open Access
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial
Background: Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency. However, its effects across different age groups remain unclear. This analysis of the Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency (IRONMAN) trial explored the efficacy and safety of FDI across age groups. Methods: The IRONMAN trial was a prospective, open-label, blinded end point randomised controlled trial enrolling patients with HFrEF and iron deficiency. This prespecified analysis stratified the population into four quarters by age group: 79 years. The primary outcome was a composite of recurrent heart failure hospitalisations and cardiovascular death. Secondary outcomes included changes in haemoglobin and quality of life. Clinical outcomes comparing FDI versus usual care in each age subgroup were analysed by the method of Lin et al for recurrent events and Cox proportional hazards model for time to first event. Interactions between age and treatment effects were explored. Results: Among 1137 randomised patients (median age 73 years), the primary outcome rate ratio (FDI vs usual care) was 0.87 (95% CI 0.61 to 1.23) in patients 79 years (p-interaction=0.38). Improvements in haemoglobin and quality of life scores at 4 months did not differ statistically across age groups (p-interaction=0.92 and 0.64, respectively). Older patients were more symptomatic at baseline, with higher N-terminal-pro B-type natriuretic peptide levels and poorer renal function, but safety outcomes did not differ across age groups. Conclusions: We found no evidence that the effects of FDI on heart failure hospitalisations, cardiovascular death, haemoglobin and quality of life differed by age. These findings support its use in patients with HFrEF and iron deficiency, including older adults. Trial registration number: NCT02642562.
Open AccessAge-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial
Background: Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency. However, its effects across different age groups remain unclear. This analysis of the Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency (IRONMAN) trial explored the efficacy and safety of FDI across age groups. Methods: The IRONMAN trial was a prospective, open-label, blinded end point randomised controlled trial enrolling patients with HFrEF and iron deficiency. This prespecified analysis stratified the population into four quarters by age group: 79 years. The primary outcome was a composite of recurrent heart failure hospitalisations and cardiovascular death. Secondary outcomes included changes in haemoglobin and quality of life. Clinical outcomes comparing FDI versus usual care in each age subgroup were analysed by the method of Lin et al for recurrent events and Cox proportional hazards model for time to first event. Interactions between age and treatment effects were explored. Results: Among 1137 randomised patients (median age 73 years), the primary outcome rate ratio (FDI vs usual care) was 0.87 (95% CI 0.61 to 1.23) in patients 79 years (p-interaction=0.38). Improvements in haemoglobin and quality of life scores at 4 months did not differ statistically across age groups (p-interaction=0.92 and 0.64, respectively). Older patients were more symptomatic at baseline, with higher N-terminal-pro B-type natriuretic peptide levels and poorer renal function, but safety outcomes did not differ across age groups. Conclusions: We found no evidence that the effects of FDI on heart failure hospitalisations, cardiovascular death, haemoglobin and quality of life differed by age. These findings support its use in patients with HFrEF and iron deficiency, including older adults. Trial registration number: NCT02642562.
- 10 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (16) , 1551-1553
Prognosis following acute myocardial infarction
- 10 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (16) , 1551-1553
Prognosis following acute myocardial infarction
- Open Access
Defining within-host SARS-CoV-2 RNA viral load kinetics during acute COVID-19 infection within different respiratory compartments and their respective associations with host infectiousness: a protocol for a systematic review and meta-analysis
Introduction Understanding how RNA viral load changes (viral load kinetics) during acute infection in SARS-CoV-2 can help to identify when and which patients are most infectious. We seek to summarise existing data on the longitudinal RNA viral load kinetics of SARS-CoV-2 sampled from different parts of the respiratory tract (nose, nasopharynx, oropharynx, saliva and exhaled breath) and how this may vary with age, sex, ethnicity, immune status, disease severity, vaccination, treatment and virus variant. Methods and analysis We will conduct a systematic review and meta-analysis, using studies identified through MEDLINE and EMBASE (via Ovid). All research studies reporting primary data on longitudinal RNA viral load kinetics of infected patients with SARS-CoV-2 will be included. Methodological quality will be assessed using a validated checklist for longitudinal studies as well as predefined quality criteria for assessment of individual-level RNA viral load. Should the data allow, we will aim to perform individual patient-level meta-analysis. Our primary outcomes are duration to, and quantity of peak RNA viral load, and total duration of viral load shedding within different respiratory compartments. Secondary outcomes include duration of lateral flow antigen and virus culture positivity and variation of RNA viral load by age, immune status, disease severity, vaccination, treatment, lateral flow tests, viral culture positivity and SARS-CoV-2 variant. Study-level effects affecting observations, but not related to properties of the patient, such as the PCR platform and gene target will also be recorded. Random-effects models will estimate the population mean and individual-level variation in viral shedding conditional on the aforementioned variables. Finally, we will summarise the key mechanistic models used in the literature to reconstruct individual-level viral kinetics and estimate how different factors shape viral dynamics over time. Ethics and dissemination Ethical approval is not needed as data will be obtained from published articles or studies with data that have already received and ethical review for analysis. Manuscript(s) will be prepared for publication. Systematic review protocol registration PROSPERO ID: CRD42023385315
Open AccessDefining within-host SARS-CoV-2 RNA viral load kinetics during acute COVID-19 infection within different respiratory compartments and their respective associations with host infectiousness: a protocol for a systematic review and meta-analysis
Introduction Understanding how RNA viral load changes (viral load kinetics) during acute infection in SARS-CoV-2 can help to identify when and which patients are most infectious. We seek to summarise existing data on the longitudinal RNA viral load kinetics of SARS-CoV-2 sampled from different parts of the respiratory tract (nose, nasopharynx, oropharynx, saliva and exhaled breath) and how this may vary with age, sex, ethnicity, immune status, disease severity, vaccination, treatment and virus variant. Methods and analysis We will conduct a systematic review and meta-analysis, using studies identified through MEDLINE and EMBASE (via Ovid). All research studies reporting primary data on longitudinal RNA viral load kinetics of infected patients with SARS-CoV-2 will be included. Methodological quality will be assessed using a validated checklist for longitudinal studies as well as predefined quality criteria for assessment of individual-level RNA viral load. Should the data allow, we will aim to perform individual patient-level meta-analysis. Our primary outcomes are duration to, and quantity of peak RNA viral load, and total duration of viral load shedding within different respiratory compartments. Secondary outcomes include duration of lateral flow antigen and virus culture positivity and variation of RNA viral load by age, immune status, disease severity, vaccination, treatment, lateral flow tests, viral culture positivity and SARS-CoV-2 variant. Study-level effects affecting observations, but not related to properties of the patient, such as the PCR platform and gene target will also be recorded. Random-effects models will estimate the population mean and individual-level variation in viral shedding conditional on the aforementioned variables. Finally, we will summarise the key mechanistic models used in the literature to reconstruct individual-level viral kinetics and estimate how different factors shape viral dynamics over time. Ethics and dissemination Ethical approval is not needed as data will be obtained from published articles or studies with data that have already received and ethical review for analysis. Manuscript(s) will be prepared for publication. Systematic review protocol registration PROSPERO ID: CRD42023385315
- Open Access
- 1 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (11) , ytae546
Takotsubo syndrome induced by de novo left bundle branch area pacing: a case report
Takotsubo syndrome (TS), traditionally associated with emotional or physical stressors, manifests as transient left ventricular (LV) abnormalities mimicking acute coronary syndrome. Surgical procedures, such as pacemaker implantation, have emerged as potential TS triggers. Conduction system pacing (CSP), including His bundle pacing and left bundle branch area pacing (LBBAP), is a novel technique utilizing the heart's intrinsic conduction system. Despite documented cases of TS post-pacemaker implantation, the literature exploring the association between CSP and TS remains sparse. In a case involving a 62-year-old woman with 2:1 atrioventricular block, an uncomplicated de novo LBBAP procedure was followed by post-procedural dizziness and dyspnoea. An initial transthoracic echocardiography revealed moderate–severe LV dysfunction, accompanied by elevated troponin levels. Coronary angiography showed unobstructed coronary arteries, while left ventriculography exhibited a classic apical ballooning. The patient had a favourable recovery, with LV function improvement noted before discharge. Takotsubo syndrome may be triggered by other non-traditional physical stressors including traditional RV pacing and LBBAP. Clinicians should be aware of this potential, albeit rare, complication of LBBAP to ensure timely recognition and management. Increased awareness is vital for optimizing patient care during CSP procedures.
- 1 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (11) , ytae546
Open AccessTakotsubo syndrome induced by de novo left bundle branch area pacing: a case report
Takotsubo syndrome (TS), traditionally associated with emotional or physical stressors, manifests as transient left ventricular (LV) abnormalities mimicking acute coronary syndrome. Surgical procedures, such as pacemaker implantation, have emerged as potential TS triggers. Conduction system pacing (CSP), including His bundle pacing and left bundle branch area pacing (LBBAP), is a novel technique utilizing the heart's intrinsic conduction system. Despite documented cases of TS post-pacemaker implantation, the literature exploring the association between CSP and TS remains sparse. In a case involving a 62-year-old woman with 2:1 atrioventricular block, an uncomplicated de novo LBBAP procedure was followed by post-procedural dizziness and dyspnoea. An initial transthoracic echocardiography revealed moderate–severe LV dysfunction, accompanied by elevated troponin levels. Coronary angiography showed unobstructed coronary arteries, while left ventriculography exhibited a classic apical ballooning. The patient had a favourable recovery, with LV function improvement noted before discharge. Takotsubo syndrome may be triggered by other non-traditional physical stressors including traditional RV pacing and LBBAP. Clinicians should be aware of this potential, albeit rare, complication of LBBAP to ensure timely recognition and management. Increased awareness is vital for optimizing patient care during CSP procedures.
- Open Access
- 23 April 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (5) , ytae214
Compatibility of transvenous implantable cardioverter defibrillator and vagus nerve stimulation device: a case report
Background: Vagus nerve stimulation (VNS) is an established therapy for drug-resistant epilepsy and depression. While VNS co-existence with cardiac pacemakers is considered safe, its interaction with implantable cardioverter defibrillators (ICDs) remains poorly understood. The concern revolves around the potential for VNS stimulation to interfere with ICD function, potentially resulting in inappropriate therapy or changes in cardiac pacing. Case summary: We present the case of a 50-year-old woman with drug-resistant epilepsy who underwent VNS device implantation and subsequent transvenous ICD placement for primary prevention post-myocardial infarction. These devices were thoughtfully situated contralaterally, with a minimum 10 cm separation. Comprehensive testing and follow-up demonstrated no interactions during device programming or serial assessments. Simultaneous interrogation of both devices with their respective telemetry wands caused chaotic artefacts in all channels on the ICD, likely due to electromagnetic interference. Importantly, this interference did not affect ICD sensing. Discussion: The co-existence of VNS and ICD in a patient is an emerging scenario with limited previous reports, yet our findings align with prior cases involving VNS and pacemakers. Emphasizing the need for optimal device separation and meticulous evaluation, particularly at maximum VNS output and ICD sensitivity settings, ensures their safe and feasible co-existence. As the use of VNS alongside cardiac implantable electronic devices becomes more common, a diligent evaluation for potential interactions is imperative. Our case highlights the successful co-existence of VNS and ICD, underscoring the importance of careful monitoring and evaluation to guarantee the safe utilization of these two devices.
- 23 April 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (5) , ytae214
Open AccessCompatibility of transvenous implantable cardioverter defibrillator and vagus nerve stimulation device: a case report
Background: Vagus nerve stimulation (VNS) is an established therapy for drug-resistant epilepsy and depression. While VNS co-existence with cardiac pacemakers is considered safe, its interaction with implantable cardioverter defibrillators (ICDs) remains poorly understood. The concern revolves around the potential for VNS stimulation to interfere with ICD function, potentially resulting in inappropriate therapy or changes in cardiac pacing. Case summary: We present the case of a 50-year-old woman with drug-resistant epilepsy who underwent VNS device implantation and subsequent transvenous ICD placement for primary prevention post-myocardial infarction. These devices were thoughtfully situated contralaterally, with a minimum 10 cm separation. Comprehensive testing and follow-up demonstrated no interactions during device programming or serial assessments. Simultaneous interrogation of both devices with their respective telemetry wands caused chaotic artefacts in all channels on the ICD, likely due to electromagnetic interference. Importantly, this interference did not affect ICD sensing. Discussion: The co-existence of VNS and ICD in a patient is an emerging scenario with limited previous reports, yet our findings align with prior cases involving VNS and pacemakers. Emphasizing the need for optimal device separation and meticulous evaluation, particularly at maximum VNS output and ICD sensitivity settings, ensures their safe and feasible co-existence. As the use of VNS alongside cardiac implantable electronic devices becomes more common, a diligent evaluation for potential interactions is imperative. Our case highlights the successful co-existence of VNS and ICD, underscoring the importance of careful monitoring and evaluation to guarantee the safe utilization of these two devices.